Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

<p>Multiplex immunohistochemical staining protocols.</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Hansol Lee (15054787) (author)
Drugi avtorji:	Angela L. Ferguson (15050051) (author), Camelia Quek (15049218) (author), Ismael A. Vergara (15054784) (author), Ines Pires daSilva (15056800) (author), Ruth Allen (15056803) (author), Tuba Nur Gide (15056806) (author), Jordan W. Conway (15056809) (author), Lambros T. Koufariotis (15056812) (author), Nicholas K. Hayward (14956488) (author), Nicola Waddell (12694196) (author), Matteo S. Carlino (15056815) (author), Alexander M. Menzies (11420816) (author), Robyn P.M. Saw (15056818) (author), Elena Shklovskaya (15056821) (author), Helen Rizos (15008946) (author), Serigne Lo (15056824) (author), Richard A. Scolyer (10778711) (author), Georgina V. Long (11420813) (author), Umaimainthan Palendira (15050084) (author), James S. Wilmott (15008931) (author)
Izdano:	2025
Teme:	Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers Prognostic biomarkers Immunology Immune responses to cancer Innate immunity Tumor-associated macrophages Immunotherapy Biomarkers for immunotherapy Checkpoint blockade Combination immunotherapy Skin Cancers Melanoma
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
od: Renumathy Dhanasekaran (14962092)
Izdano: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
od: Hiroshi Kagamu (14961732)
Izdano: (2025)

Supplementary File 1 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
od: Huaibin Ge (15047462)
Izdano: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Izdano: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Izdano: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Izdano: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Izdano: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Izdano: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
od: Daniel S. Green (15047598)
Izdano: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
od: Carlotta Antoniotti (15352506)
Izdano: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
od: Carlotta Antoniotti (15352506)
Izdano: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
od: Carlotta Antoniotti (15352506)
Izdano: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Izdano: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Izdano: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Izdano: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Izdano: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S4 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S6A from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S6B from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
od: Sahar Mafi (16721657)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_66c2pcv0hk7jvl4jabe2d0m1g9